11 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
...ew assays which might potentially used for future clinical trials for influenza seasonal vaccine evaluationFLUCOP Consortium and Project Impact: The FLUCOP consortium brings together 26 groups from 7 European countries, and includes contributors from the academic, governmental, non-for-profit and pharmaceutical sectors. As a whole, the consortium has a balanced array of expertise and each group ha ...
Voir le projet
26
Participants partenaires
TERMINÉ
Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure (EDUFLUVAC)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
"As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC ai ...
Voir le projet
9
Participants partenaires
TERMINÉ
A Multi-Stage Malaria Vaccine (MultiMalVax)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
...ccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product.
Voir le projet
6
Participants partenaires
TERMINÉ
Clinical development of a VAR2CSA-based placental malaria vaccine (PLACMALVAC)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
...d they have been collaborating with Institut de Recherche pour le Developpement (IRD) and Université d'Abomey-Calavi (UAC) to optimize vaccine antigens and to prepare sites for clinical testing. The European Vaccine Initiative (EVI) will provide product management and coordinate execution of the phase I clinical trial. Thus, this study will provide a product to continue into efficacy studies in Af ...
Voir le projet
6
Participants partenaires
TERMINÉ
comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN (BELLEROPHON)
Date du début: 1 sept. 2013, Date de fin: 31 août 2016,
"Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals.Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to ...
Voir le projet
4
Participants partenaires
TERMINÉ
Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE)
Date du début: 1 déc. 2013, Date de fin: 31 mars 2016,
Under the leadership of the major Europe-based vaccine industry players, IPROVE (Innovation Partnership for a Roadmap on Vaccines in Europe) will produce a comprehensive roadmap on the future of vaccine R&D, production and delivery in the EU. IPROVE aims to drive current EU research efforts towards the establishment of a clear vision of the priority innovations and technologies necessary to addres ...
Voir le projet
5
Participants partenaires
TERMINÉ
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA)
Date du début: 1 mars 2010, Date de fin: 31 août 2015,
...by worm co-infections of vaccine-induced immune responses. To achieve these objectives, IDEA project has developed a global and innovative strategy which includes: a) the alliance between African and European leading scientists in the field of worms, HIV, TB and malaria, b) the multidisciplinary expertise involving immunologists, parasitologists, epidemiologists, clinicians, and experts in vaccine ...
Voir le projet
23
Participants partenaires
TERMINÉ
European Network of Vaccine Development and Research (TRANSVAC)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
...guably, fragmentation of expertise and facilities has slowed, and in some instances distinctly impeded, the development and validation of promising vaccine candidates. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals. The European Vaccine Initiative (EVI) and the Tuberculos ...
Voir le projet
18
Participants partenaires
TERMINÉ
Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation (OPTIMALVAC)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2012,
"A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidem ...
Voir le projet
14
Participants partenaires
TERMINÉ
"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges." (INYVAX)
Date du début: 1 févr. 2009, Date de fin: 31 janv. 2012,
...re-clinical criteria. 3) the development of information-sharing tools to strengthen connections between the scientists, the developers and the clinical investigators. To address those challenges, the European vaccine community needs to establish a shared vision and goals and to identify the activities that could address some of the above-mentioned challenges. The cooperation between the different ...
Voir le projet
10
Participants partenaires
TERMINÉ
Platform for the Harmonization of Vaccine Adjuvant Testing (PHARVAT)
Date du début: 1 nov. 2009, Date de fin: 31 oct. 2011,
"Adjuvants are critical to the quality and magnitude of immune responses generated by PRD vaccines. However, vaccine development is hampered by lack of access to appropriate adjuvants. This is partly because adjuvants are developed in many organizations, with individual models and protocols that have been established independently. The resulting data on adjuvants are only rarely directly comparabl ...
Voir le projet